Skip to main content
CTSO logo

CTSO · Cytosorbents Corp · Webcasts, Transcripts & Audio

Track CTSO — free
$4.00 -0.05 (-1.23%)
Market Cap
$12.61M
Shares
3.14M
Volume · Oct 5 5878 Avg daily vol (18 sessions) 12.3K

Cytosorbents Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Cytosorbents Corp (CTSO), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q2
2026-08-06
Cytosorbents Corp (CTSO) Q2 2026 Earnings Call Transcript
Positive tone Cytosorb commercial sales and Germany restructuring HemaDefend BGA universal plasma strategic optionality Operating cash flow break-even progress
Revenue
$9.63M
▲ 0.2% YoY
Diluted EPS
$-1.40
▼ 333.3% YoY
Gross margin
73.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-13
Cytosorbents Corp (CTSO) Q1 2026 Earnings Call Transcript
Positive tone DrugSorb-ATR U.S. regulatory pathway Core CytoSorb international commercial performance Geopolitical disruption in the Middle East
Revenue
$8.86M
▲ 1.6% YoY
Diluted EPS
$-1.60
Gross margin
69.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-25
Cytosorbents Corp (CTSO) Q4 2025 Earnings Call Transcript
Positive tone DrugSorb-ATR FDA resubmission Germany restructuring and sales recovery Path to operating cash flow break-even
Revenue
$9.23M*
▲ 0.9% YoY
Gross margin
73.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-13
Cytosorbents Corp (CTSO) Q3 2025 Earnings Call Transcript
Positive tone DrugSorb-ATR FDA Pathway Germany Sales Restructuring Cash Flow Breakeven Path
Revenue
$9.48M
▲ 10.1% YoY
Diluted EPS
$-1.00
Gross margin
70.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Cytosorbents Corp (CTSO) Q2 2025 Earnings Call Transcript
Positive tone CytoSorb product and sepsis clinical evidence DrugSorb ATR regulatory process Gross margin performance
Revenue
$9.62M
▲ 8.8% YoY
Diluted EPS
$0.60
Gross margin
70.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
Cytosorbents Corp (CTSO) Q1 2025 Earnings Call Transcript
Positive tone DrugSorb-ATR regulatory status Core CytoSorb business performance Germany sales reorganization
Revenue
$8.73M
▼ 2.9% YoY
Diluted EPS
$-0.40
Gross margin
71.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Cytosorbents Corp (CTSO) Q4 2024 Earnings Call
Revenue
$9.15M*
▲ 5.6% YoY
Gross margin
68.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-01
Cytosorbents Corp (CTSO) Q3 2024 Earnings Call Transcript
Positive tone DrugSorb ATR U.S. and Canada regulatory pathway CytoSorb international core business growth PuriFi pump as enabling technology
Revenue
$8.61M
▼ 2.2% YoY
Diluted EPS
$-1.00
Gross margin
61.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Cytosorbents Corp (CTSO) Q2 2024 Earnings Call Transcript
Positive tone DrugSorb-ATR Regulatory Submission Revenue and Product Sales Growth Taiwan Market Opportunity
Revenue
$8.84M
▼ 6.1% YoY
Diluted EPS
$-1.60
Gross margin
73.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Cytosorbents Corp (CTSO) Q1 2024 Earnings Call Transcript
Positive tone DrugSorb-ATR regulatory submissions Clinical evidence and new indications Product sales growth and post-COVID recovery
Revenue
$8.99M
▼ 4.9% YoY
Diluted EPS
$-2.20
Gross margin
76.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-15
Cytosorbents Corp (CTSO) Q4 2023 Earnings Call Transcript
Balanced tone STAR-T trial and regulatory pathway for DrugSorb-ATR India distribution partnership with Eris Lifesciences/ARRIS Sales performance and growth across regions
Revenue
$8.67M
▼ 7.7% YoY
Diluted EPS
$-2.40
Gross margin
61.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Cytosorbents Corp (CTSO) Q3 2023 Earnings Call Transcript
Revenue
$8.81M
▲ 8.6% YoY
Diluted EPS
$-4.20
Gross margin
63.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-02
Cytosorbents Corp (CTSO) Q2 2023 Earnings Call Transcript
Revenue
$9.42M
▲ 10.9% YoY
Diluted EPS
$-3.00
Gross margin
63.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Cytosorbents Corp (CTSO) Q1 2023 Earnings Call Transcript
Revenue
$9.45M
▲ 8.7% YoY
Diluted EPS
$-3.40
Gross margin
57.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-09
Cytosorbents Corp (CTSO) Q4 2022 Earnings Call Transcript
Revenue
$9.39M
▼ 12.9% YoY
Diluted EPS
$-0.40
Gross margin
61.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Cytosorbents Corp (CTSO) Q3 2022 Earnings Call Transcript
Revenue
$8.11M
▼ 16.9% YoY
Diluted EPS
$-5.60
Gross margin
44.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Cytosorbents Corp (CTSO) Q2 2022 Earnings Call Transcript
Revenue
$8.50M
▼ 29.3% YoY
Diluted EPS
$-5.00
Gross margin
58.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Cytosorbents Corp (CTSO) Q1 2022 Earnings Call Transcript
Revenue
$8.69M
▼ 18% YoY
Diluted EPS
$-4.20
Gross margin
73.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Cytosorbents Corp (CTSO) Q4 2021 Earnings Call Transcript
Revenue
$10.78M
▼ 9.8% YoY
Diluted EPS
$-5.00
Gross margin
71.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-10-13
Cytosorbents Corp (CTSO) Q3 2021 Earnings Call Transcript
Revenue
$9.76M
▼ 7.5% YoY
Diluted EPS
$-3.00
Gross margin
74.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-04
Cytosorbents Corp (CTSO) Q2 2021 Earnings Call Transcript
Revenue
$12.02M
▲ 22.8% YoY
Diluted EPS
$-2.20
Gross margin
77.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Cytosorbents Corp (CTSO) Q1 2021 Earnings Call Transcript
Revenue
$10.60M
▲ 21.7% YoY
Diluted EPS
$-2.00
Gross margin
74.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-09
Cytosorbents Corp (CTSO) Q4 2020 Earnings Call Transcript
Revenue
$11.96M
▲ 60.9% YoY
Diluted EPS
$0.00
Gross margin
78.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Cytosorbents Corp (CTSO) Q3 2020 Earnings Call Transcript
Revenue
$10.55M
▲ 73% YoY
Diluted EPS
$-0.40
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Cytosorbents Corp (CTSO) Q2 2020 Earnings Call Transcript
Revenue
$9.79M
▲ 57.2% YoY
Diluted EPS
$-1.60
Gross margin
66.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Cytosorbents Corp (CTSO) Q1 2020 Earnings Call Transcript
Revenue
$8.71M
▲ 67.7% YoY
Diluted EPS
$-2.00
Gross margin
72.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Cytosorbents Corp (CTSO) Q4 2019 Earnings Call
Revenue
$7.43M
▲ 22.2% YoY
Diluted EPS
$-2.60
Gross margin
71.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–27 of 27 webcasts
Key facts CIK 1175151 CUSIP 23283X206 13F (30d) 1 filings 1 filers Visit website Investor relations